ClinicalTrials.gg
CompletedNCT00303524Updated Dec 23, 2009

Comparative Study of Oestradiol Suppression: Zoladex 10.8mg/3 Month vs. 3.6mg/Month in ER +ve EBC Pre-menopausal Patients

A Phase 2 interventional study of Goserelin acetate and Goserelin acetate in Breast Cancer, sponsored by AstraZeneca. Completed at 22 sites in Japan. Open to female participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2009-12-23.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
20 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing goserelin in Breast Neoplasms — 7 open to participants now, 9 under way, none of them phase 3. Goserelin · Breast Neoplasms.

Enrollment
19th of 41
170 · median 147
Started
2006
with 2 others
Phase 2
21 of 43
6 open now
Registered
7th of 43
by date
Lead sponsor
5 of 43
AstraZeneca

Among the 43 studies testing goserelin in Breast Neoplasms, this one is the 19th largest by enrollment of the 41 interventional ones that give a count, is one of 3 that started in 2006, is one of 21 in phase 2, and was the 7th registered.

Breast Neoplasms

14,840 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 43 studies testing goserelin in Breast Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About goserelin

Goserelin: first FDA approval 1989 (ZOLADEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,398 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 590 (25%) stop at 75 or younger; 103 take children under 18; 213 take healthy volunteers.

This study: 20 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing goserelin in Breast Neoplasms, or all of them as a file.
02

Study summary

The primary purpose of this study is to establish if a 10.8 mg dose of ZOLADEX given 3 monthly is non-inferior to a 3.6 mg dose of ZOLADEX given monthly in terms of oestradiol suppression in patients with oestrogen receptor positive early breast cancer.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pre-menopausal women aged 20 years or over with histological/-confirmed ER +ve breast cancer who have undergone radical surgery and 0,1 or 2.

Exclusion criteria

Exclusion Criteria:

  • Evidence of disease, previous bilateral oophorectomy or radiotherapy to the ovaries, previous chemotherapy, breast surgery completed over 12 weeks before starting trial treatment, previous /adjuvant hormonal breast cancer therapy
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
170 participants (actual)

Study arms

  • Experimental
    1

    Zoladex 3-month depot

    Drug: Goserelin acetate

  • Experimental
    2

    Zoladex 1-month depot

    Drug: Goserelin acetate

Interventions

06

What researchers measure

Primary outcomes

  1. Zoladex 10.8mg depot (every 12 weeks) is non-inferior to Zoladex 3.6mg depot (every 4 weeks) in terms of oestradiol (E2) suppression in patient population by assessment of area under the curve of E2 concentration during the first 24 weeks of treatment.

    Time frame: every 12 weeks

Secondary outcomes

  1. Zoladex 10.8mg has similar safety and tolerability profile to Zoladex 3.6mg. Examination of goserelin pharmacokinetics (PK) in Japanese patients after injection of Zoladex 10.8mg. Efficacy of Zoladex 10.8mg is similar to 3.6mg by assessment of DFS.

    Time frame: every 12 weeks

07

Study locations

22 sites
  • Research Site
    Chiba, Japan
  • Research Site
    Fukuoka, Japan
  • Research Site
    Fukushima, Japan
  • Research Site
    Isehara, Japan
  • Research Site
    Kagoshima, Japan
  • Research Site
    Kashiwa, Japan
  • Research Site
    Kawasaki, Japan
  • Research Site
    Kitakyushu, Japan
  • Research Site
    Kumamoto, Japan
  • Research Site
    Matsuyama, Japan
  • Research Site
    Miyazaki, Japan
  • Research Site
    Nagoya, Japan
  • Research Site
    Niigata, Japan
  • Research Site
    Osakasayama, Japan
  • Research Site
    Osaka, Japan
  • Research Site
    Ota, Japan
  • Research Site
    Saitama, Japan
  • Research Site
    Shimotsuke, Japan
  • Research Site
    Suita, Japan
  • Research Site
    Tokorozawa, Japan
  • Research Site
    Tokyo, Japan
  • Research Site
    Utsunomiya, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2006, a primary completion of Aug 2007 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2006
First posted
Mar 17, 2006
Start
Feb 2006
Primary completionActual
Aug 2007
CompletionActual
Feb 2009
Last update
Dec 23, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00303524
Lead sponsor
AstraZeneca
First posted
Mar 17, 2006
Start date
Feb 2006
Primary completion
Aug 2007
Completion
Feb 2009
Last update
Dec 23, 2009

Study contacts

AstraZeneca Japan Medical Director, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Goserelin

Start the discussion